AI study of tumor burden on PSMA PET-CT scans

This study tests an artificial intelligence (AI) tool that may improve how doctors detect prostate cancer using imaging and biopsy information. It could help better identify cancer that is suspected based on PSA blood tests and rectal exam findings.

This trial studies how AI might improve the process of prostate biopsies for people who have had an MRI. It may help if you are scheduled for a biopsy and have not been treated for prostate cancer before.

This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.

This study allows people with prostate cancer to get a special PET scan that finds cancer cells. The scan helps doctors plan the best treatment. You may qualify if your PSA is rising or you have high-risk prostate cancer.

This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.

This study compares how well a doctor’s MRI reading (the PI-RADS score) and a computer AI tool detect prostate cancer. It may help improve how men get targeted biopsies and avoid missing important cancers.